2018 John Charnley Award: Analysis of US Hip Replacement Bundled Payments: Physician-initiated Episodes Outperform Hospital-initiated Episodes.
Arthroplasty, Replacement, Hip
/ adverse effects
Awards and Prizes
Centers for Medicare and Medicaid Services, U.S.
/ economics
Cost Savings
Cost-Benefit Analysis
Databases, Factual
Fee-for-Service Plans
/ economics
Group Practice
/ economics
Hospital Costs
Humans
Outcome and Process Assessment, Health Care
/ economics
Patient Care Bundles
/ adverse effects
Patient Readmission
/ economics
Physician Executives
Postoperative Complications
/ economics
Program Evaluation
Retrospective Studies
Risk Factors
Time Factors
Treatment Outcome
United States
Journal
Clinical orthopaedics and related research
ISSN: 1528-1132
Titre abrégé: Clin Orthop Relat Res
Pays: United States
ID NLM: 0075674
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
entrez:
22
1
2019
pubmed:
22
1
2019
medline:
19
11
2019
Statut:
ppublish
Résumé
The Centers for Medicare & Medicaid Services (CMS) launched the Bundled Payment for Care Improvement (BPCI) initiative in 2013 to create incentives to improve outcomes and reduce costs in various clinical settings, including total hip arthroplasty (THA). This study seeks to quantify BPCI initiative outcomes for THA and to determine the optimal party (for example, hospital versus physician group practice [PGP]) to manage the program. (1) Is BPCI associated with lower 90-day payments, readmissions, or mortality for elective THA? (2) Is there a difference in 90-day payments, readmissions, or mortality between episodes initiated by PGPs and episodes initiated by hospitals for elective THA? (3) Is BPCI associated with reduced total Elixhauser comorbidity index or age for elective THA? We performed a retrospective analysis on the CMS Limited Data Set on all Medicare primary elective THAs without a major comorbidity performed in the United States (except Maryland) between January 2013 and March 2016, totaling more than USD 7.1 billion in expenditures. Episodes were grouped into hospital-run BPCI (n = 42,922), PGP-run BPCI (n = 44,662), and THA performed outside of BPCI (n = 284,002). All Medicare Part A payments were calculated over a 90-day period after surgery and adjusted for inflation and regional variation. For each episode, age, sex, race, geographic location, background trend, and Elixhauser comorbidities were determined to control for major confounding variables. Total payments, readmissions, and mortality were compared among the groups with logistic regression. When controlling for demographics, background trend, geographic variation, and total Elixhauser comorbidities in elective Diagnosis-Related Group 470 THA episodes, BPCI was associated with a 4.44% (95% confidence interval [CI], -4.58% to -4.30%; p < 0.001) payment decrease for all participants (USD 1244 decrease from a baseline of USD 18,802); additionally, odds ratios (ORs) for 90-day mortality and readmissions were unchanged. PGP groups showed a 4.81% decrease in payments (95% CI, -5.01% to -4.61%; p < 0.001) after enrolling in BPCI (USD 1335 decrease from a baseline of USD 17,841). Hospital groups showed a 4.04% decrease in payments (95% CI, -4.24% to 3.84%; p < 0.01) after enrolling in BPCI (USD 1138 decrease from a baseline of USD 19,799). The decrease in payments of PGP-run episodes was greater compared with hospital-run episodes. ORs for 90-day mortality and readmission remained unchanged after BPCI for PGP- and hospital-run BPCI programs. Patient age and mean Elixhauser comorbidity index did not change after BPCI for PGP-run, hospital-run, or overall BPCI episodes. Even when controlling for decreasing costs in traditional fee-for-service care, BPCI is associated with payment reduction with no change in adverse events, and this is not because of the selection of younger patients or those with fewer comorbidities. Furthermore, physician group practices were associated with greater payment reduction than hospital programs with no difference in readmission or mortality from baseline for either. Physicians may be a more logical group than hospitals to manage payment reduction in future healthcare reform. Level II, economic and decision analysis.
Sections du résumé
BACKGROUND
The Centers for Medicare & Medicaid Services (CMS) launched the Bundled Payment for Care Improvement (BPCI) initiative in 2013 to create incentives to improve outcomes and reduce costs in various clinical settings, including total hip arthroplasty (THA). This study seeks to quantify BPCI initiative outcomes for THA and to determine the optimal party (for example, hospital versus physician group practice [PGP]) to manage the program.
QUESTIONS/PURPOSES
(1) Is BPCI associated with lower 90-day payments, readmissions, or mortality for elective THA? (2) Is there a difference in 90-day payments, readmissions, or mortality between episodes initiated by PGPs and episodes initiated by hospitals for elective THA? (3) Is BPCI associated with reduced total Elixhauser comorbidity index or age for elective THA?
METHODS
We performed a retrospective analysis on the CMS Limited Data Set on all Medicare primary elective THAs without a major comorbidity performed in the United States (except Maryland) between January 2013 and March 2016, totaling more than USD 7.1 billion in expenditures. Episodes were grouped into hospital-run BPCI (n = 42,922), PGP-run BPCI (n = 44,662), and THA performed outside of BPCI (n = 284,002). All Medicare Part A payments were calculated over a 90-day period after surgery and adjusted for inflation and regional variation. For each episode, age, sex, race, geographic location, background trend, and Elixhauser comorbidities were determined to control for major confounding variables. Total payments, readmissions, and mortality were compared among the groups with logistic regression.
RESULTS
When controlling for demographics, background trend, geographic variation, and total Elixhauser comorbidities in elective Diagnosis-Related Group 470 THA episodes, BPCI was associated with a 4.44% (95% confidence interval [CI], -4.58% to -4.30%; p < 0.001) payment decrease for all participants (USD 1244 decrease from a baseline of USD 18,802); additionally, odds ratios (ORs) for 90-day mortality and readmissions were unchanged. PGP groups showed a 4.81% decrease in payments (95% CI, -5.01% to -4.61%; p < 0.001) after enrolling in BPCI (USD 1335 decrease from a baseline of USD 17,841). Hospital groups showed a 4.04% decrease in payments (95% CI, -4.24% to 3.84%; p < 0.01) after enrolling in BPCI (USD 1138 decrease from a baseline of USD 19,799). The decrease in payments of PGP-run episodes was greater compared with hospital-run episodes. ORs for 90-day mortality and readmission remained unchanged after BPCI for PGP- and hospital-run BPCI programs. Patient age and mean Elixhauser comorbidity index did not change after BPCI for PGP-run, hospital-run, or overall BPCI episodes.
CONCLUSIONS
Even when controlling for decreasing costs in traditional fee-for-service care, BPCI is associated with payment reduction with no change in adverse events, and this is not because of the selection of younger patients or those with fewer comorbidities. Furthermore, physician group practices were associated with greater payment reduction than hospital programs with no difference in readmission or mortality from baseline for either. Physicians may be a more logical group than hospitals to manage payment reduction in future healthcare reform.
LEVEL OF EVIDENCE
Level II, economic and decision analysis.
Identifiants
pubmed: 30664603
doi: 10.1097/CORR.0000000000000532
pii: 00003086-201902000-00003
pmc: PMC6370097
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
271-280Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001102
Pays : United States
Références
J Arthroplasty. 2017 Aug;32(8):2590-2597
pubmed: 28438453
Am J Manag Care. 2015 Nov;21(11):814-20
pubmed: 26633254
J Arthroplasty. 2015 Dec;30(12):2045-56
pubmed: 26077149
Ann Transl Med. 2015 May;3(Suppl 1):S38
pubmed: 26046085
JAMA. 2016 Sep 27;316(12):1267-78
pubmed: 27653006
J Arthroplasty. 2016 Jul;31(7):1400-1406.e3
pubmed: 26880328
J Arthroplasty. 2017 Aug;32(8):2332-2338
pubmed: 28433428
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Health Aff (Millwood). 2016 Sep 1;35(9):1651-7
pubmed: 27605647
J Bone Joint Surg Am. 2014 Jul 16;96(14):1201-1209
pubmed: 25031375
Med Care. 1998 Jan;36(1):8-27
pubmed: 9431328
J Orthop Trauma. 2016 Dec;30 Suppl 5:S50-S53
pubmed: 27870676
J Arthroplasty. 2017 Jun;32(6):1717-1719
pubmed: 28318863
J Bone Joint Surg Am. 2017 Jan 4;99(1):e2
pubmed: 28060238
J Arthroplasty. 2014 Sep;29(9):1717-22
pubmed: 24814806
J Arthroplasty. 2015 Mar;30(3):353-5
pubmed: 25680450
Instr Course Lect. 2016;65:555-66
pubmed: 27049220
N Engl J Med. 2009 Sep 10;361(11):1033-6
pubmed: 19692682
J Arthroplasty. 2017 Dec;32(12):3563-3567
pubmed: 28735805
J Arthroplasty. 2017 Nov;32(11):3274-3285
pubmed: 28669571
J Arthroplasty. 2016 May;31(5):938-44
pubmed: 27131095
JAMA Intern Med. 2017 Feb 1;177(2):214-222
pubmed: 28055062
J Arthroplasty. 2017 Oct;32(10):2931-2934
pubmed: 28583761
J Arthroplasty. 2016 Dec;31(12):2710-2713
pubmed: 27344351
J Arthroplasty. 2013 Oct;28(9):1513-20
pubmed: 23845765
Tex Heart Inst J. 1995;22(1):72-6
pubmed: 7787473
J Bone Joint Surg Am. 2016 Dec 7;98(23):1949-1953
pubmed: 27926675